Accesswire First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024Clinical supply agreement for acalabrutinib with AstraZeneca in...\n more…
TipRanks Financial Blog In a report released on September 10, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN - Research Report), with a price...\n more…
Ticker Report Private Advisor Group LLC grew its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 7.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange...\n more…